OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share. OKYO is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market.

According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

Argus Jul 22 session 6 alerts

+5.56% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – OKYO

+4.3% Peak in 25 min

$71.90M Mkt Cap at Peak Alert

On Jul 22, the day this news came out, OKYO closed 5.56% above the previous close. Argus tracked a peak move of +4.3% during that session. Our momentum scanner recorded 6 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 22 session.

Key Figures

Shares purchased: 20,000 ordinary shares Purchase price: $1.40 per share Trial phase: Phase 3 +1 more

Shares purchased

20,000 ordinary shares

Chief Medical Officer open-market purchase

Purchase price

$1.40 per share

NASDAQ transaction

Trial phase

Phase 3

Global pivotal clinical trial planned for the second half of this year

Planned enrollment

Approximately 111 patients

Global trial evaluating urcosimod for neuropathic corneal pain

Historical Context

5 past events · Latest: Jul 20

5 events

1. Jul 20

   Annual report update

   24h Move

   -4.2%

   Reported stronger funding and plans for the global Phase 3 NEPTUNE trial.

2. Jul 08

   FDA trial update

   24h Move

   -5.1%

   FDA feedback supported advancing urcosimod into a global Phase 3 pivotal trial.

3. Jul 07

   Conference participation

   24h Move

   +8.7%

   Company announced executive participation in a virtual ophthalmology symposium.

4. May 19

   Advisory board appointment

   24h Move

   -0.0%

   OKYO appointed ophthalmology expert Marta Sacchetti to its scientific advisory board.

5. Apr 29

   Scientific conference plans

   24h Move

   -3.8%

   Executives announced presentations and participation at upcoming scientific meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuropathic corneal pain, phase 3, single-dose regimen

3 terms

neuropathic corneal pain medical

"therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

phase 3 medical

"initiate a global Phase 3 pivotal clinical trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

single-dose regimen medical

"evaluate a single-dose regimen of urcosimod"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO Pharma (NASDAQ: OKYO) announce on July 22, 2026?

OKYO Pharma announced that Chief Medical Officer Flavio Mantelli purchased 20,000 ordinary shares at $1.40 per share. According to OKYO Pharma, this transaction occurred on Nasdaq and involved the company’s ordinary shares listed on the Nasdaq Capital Market.

How many OKYO Pharma shares did the Chief Medical Officer buy and at what price?

OKYO Pharma’s Chief Medical Officer bought 20,000 ordinary shares at a price of $1.40 per share. According to OKYO Pharma, these shares were purchased on Nasdaq, where the company’s ordinary shares are listed for trading on the Nasdaq Capital Market.

What clinical trial is OKYO Pharma (OKYO) planning for neuropathic corneal pain?

OKYO Pharma plans a global Phase 3 pivotal trial evaluating urcosimod for neuropathic corneal pain. According to OKYO Pharma, the trial is expected in the second half of this year and will enroll about 111 patients on a single-dose regimen of urcosimod.

When will OKYO Pharma start its Phase 3 urcosimod trial and how many patients are planned?

OKYO Pharma plans to initiate the Phase 3 urcosimod trial in the second half of this year, enrolling approximately 111 patients. According to OKYO Pharma, the study will assess a single-dose regimen for treating neuropathic corneal pain (NCP).

What therapeutic areas does OKYO Pharma focus on with ticker OKYO on Nasdaq?

OKYO Pharma focuses on developing therapies for neuropathic corneal pain and anterior segment eye diseases. According to OKYO Pharma, it is a clinical-stage biopharmaceutical company with ordinary shares listed for trading on the Nasdaq Capital Market under the symbol OKYO.

What is urcosimod in OKYO Pharma’s pipeline for neuropathic corneal pain (NCP)?

Urcosimod is OKYO Pharma’s investigational therapy being advanced for neuropathic corneal pain. According to OKYO Pharma, a global Phase 3 pivotal clinical trial is planned, using a single-dose regimen in approximately 111 patients to evaluate urcosimod in NCP.